Abstract:The protein tyrosine phosphatase nonreceptor type 12 (PTPN12) is a multifunctional protein and has elicited much research attention because its decreased protein level has been associated with poor prognosis of several types of cancers. Recently, we have solved the crystal structure of the phosphatase domain of PTPN12, which disclosed a specific PTPN12-insert-loop harboring a cyclin-dependent kinase 2 (CDK2) phosphorylation site. However, the functional significance of this phosphorylation is undefined. In the present study, we found that S19 site phosphorylation of PTPN12 by CDK2 discharged its antitumor activity by down-regulation of its inhibitory role in cell migration, but not affecting its other regulatory functions. Phosphorylation of PTPN12 at the S19 site changed its substrate interface, and by doing so, selectively decreased its activity toward the human epidermal growth factor receptor 2 (HER2)- pY1196 site, but not other HER2 phosphorylation sites or other known PTPN12 substrates. A further in-depth mechanism study revealed that the phosphorylation of PTPN12 by CDK2 impaired recruitment of the serine/threonine-protein kinase 1 (PAK1) to HER2, resulted in the blockade of the HER2-pY1196-PAK1-T423 signaling pathway, thus increased tumor cell motility. Taken together, our results identified a new phosphorylation-based substrate recognition mechanism of PTPN12 by CDK2, which orchestrated signaling crosstalk between the oncogenic CDK2 and HER2 pathways. The newly identified governing mechanism of the substrate selectivity of a particular phosphatase was previously unappreciated and exemplifies how a phospho-network is precisely controlled in different cellular contexts.-Li, H., Yang, D., Ning, S., Xu, Y., Yang, F., Yin, R., Feng, T., Han, S., Guo, L., Zhang, P., Qu, W., Guo, R., Song, C., Xiao, P., Zhou, C., Xu, Z., Sun, J.-P., Yu, X. Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways.

Activation loop phosphorylation of Cdk11 is restrained by PNUTS-PP1 and regulates Cdk11 activity and function

Switching of the Substrate Specificity of Protein Tyrosine Phosphatase N12 by Cyclin‐dependent Kinase 2 Phosphorylation Orchestrating 2 Oncogenic Pathways

PAF1C allosterically activates CDK12/13 kinase during RNAPII transcript elongation

Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function

Coordinate control of the RNA polymerase II transcription cycle by CDK9-dependent, tripartite phosphorylation of SPT5

The CDK9-SPT5 axis in control of transcription elongation by RNAPII

The Establishment of a Hyperactive Structure Allows the Tumour Suppressor Protein p53 to Function through P-TEFb during Limited CDK9 Kinase Inhibition

CDK11, a splicing-associated kinase regulating gene expression

Site-specific Proteasome Phosphorylation Controls Cell Proliferation and Tumorigenesis

Distinct Cdk9-phosphatase switches act at the beginning and end of elongation by RNA polymerase II

CK1δ Activity is Modulated by CDK2/E- and CDK5/p35-mediated Phosphorylation

PP1 PNUTS binds the restrictor and dephosphorylates RNA pol II CTD Ser5 to stimulate transcription termination

The Phosphatase PP1 Sustains Global Transcription by Promoting RNA Polymerase II Pause Release

Regulation of a transcription factor network by Cdk1 coordinates late cell cycle gene expression

A cyclin-dependent kinase, CDK11/p58, represses cap-dependent translation during mitosis

CDK11 Requires a Critical Activator SAP30BP to Regulate Pre‐mrna Splicing

PP2B and PP1α cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca<sup>2+</sup> signaling

CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1

Context-dependent Modulation of Pol II CTD Phosphatase SSUP-72 Regulates Alternative Polyadenylation in Neuronal Development.

CDK9 keeps RNA polymerase II on track

Phase-separation mechanism for C-terminal hyperphosphorylation of RNA polymerase II